Exploring and exploiting the potential of pelvic IMRT to spare the bowel by Hysing, Liv Bolstad
Exploring and exploiting the potential of
pelvic IMRT to spare the bowel
Liv Bolstad Hysing
Dissertation for the degree of Philosophiae Doctor (PhD)
at the University of Bergen
2011
Dissertation date: 28.10.2011

’When a measure becomes a target,
it ceases to be a good measure.’ 1
1Goodhart’s law warn us against the focus on impact factors. From Arnold and Fowler 2011; Nefarious
numbers [3]

Scientiﬁc Environment
The work of this thesis has been carried out at the Section of Medical Physics, Department of
Oncology and Medical Physics at Haukeland University Hospital in Bergen, Norway as well
as at the Section of Biomedical Physics at the University Clinic for Radiooncology, Tübingen,
Germany. The candidate has formally been connected to the Institute of Biomedicine, Faculty
of Medicine and Dentistry at the University of Bergen during the PhD-period. The work has
been supported ﬁnancially by Western Norway Regional Health Authority.

Acknowledgements
First and foremost I want to thank my supervisors Ludvig Muren, Markus Alber, Yngve
Kvinnsland and Arvid Lundervold. Each and everyone of you have played a different but
important role contributing to the ﬁnalization of this thesis.
If it wouldn’t be for you, Ludvig, I would never have started this PhD in the ﬁrst place.
Always optimistic and understanding, you were patiently teaching me everything you knew
about radiotherapy and research. From day one you have believed in me and slowly built
my self conﬁdence by providing me with new challenges and loads of motivation to reach
them. With time you’ve given me the freedom and trust to become independent, to ﬁnd my
own ways and to build my own networks. Nevertheless, you are always accessible and steady
in the background carefully listening to my enthusiasm or problems and always alert to help
when needed.
Thank you, Markus, for introducing me to the art of research and tango dancing. I under-
stood early that I could learn a lot from you. After each meeting I had to use weeks to analyze
what you said. Thank you for answering my stupid questions, for your patience and honesty. I
always felt safe that you saw the light at the end of the tunnel, and that I would also see it one
day. Being part of your team has given me perspectives. For sure, this PhD would have looked
much different without your skilled ideas.
Many thanks to Yngve for being the critical and realistic counterpart of Ludvig. You were
always to the point translating ambitious ideas into hard work. Thank you also for introducing
me into the world of programming with all its possibilities. Your unique combination of good
judgement with a good sence of humour and easy going nature, make it easy to trust in you.
I’m happy to know you both as a friend and colleague.
I also want to thank Arvid. Formally for afﬁliating me to the istitute of Biomedicine, but
also for our cooperation in MedViz. Your busy but always positive and enthusiastic nature has
been a great source of inspiration. You made me realize the importance of good communica-
tion and power of interdisiplinarity.
Throughout these years I have been priviliged to work together with and build friendships
with a number of people in Bergen, Tübingen and Aarhus. Thanks to all my colleagues at
Section of medical physics at Haukeland for contributing to a humorous, inclusive and skilled
working environment. You are doing an important job, and you do it well! My ﬁrst ofﬁce-mate
Ellen Wasbø deserve special thanks for being a wonderful person and for sharing her enthusi-
asm, ideas and knowledge with me. You truly make the world a better place. Eva Marki and
Monica Off should be mentioned for making a joyable atmosphere in our current ofﬁce. Tone
Nybø for contributing with her clinical knowledge and for spreading humour. I will always
remember ’Gratulieren mit deinem tag..’. Svein Inge Helle has as responsible for prostate can-
cer patients at our clinic also been an important project partner, always positive and helpful
despite his busy schedule. Tore Wentzel-Larsen has contributed with his statistical knowledge.
Working together with Are Losnegård through our MedViz cooperation has been enjoyable
both on a scientiﬁc and personal level. Thanks for all the excellent coffee and for being such
an easy-going, positive ’kjernekar’.
Thanks to all my former colleagues in Tübingen for making my stay there an unforgettable
time. Marcin Sikora whom I proudly managed to kidnap to Bergen. Matthias Söhn for your
unique personality and skills. Benjamin Sobotta for our good laughs and discussions and for
being a great source of inspiration during our time in the same ofﬁce. Martin Soukup for
always being helpful and enjoying good conversations over beer. Daniela Thorwarth for being
a good role model and teaching me about german culture. Bettina Frey and Zanzem Atem Tung
for guidance with bowel contouring. Oliver Dohm, Philip Oberhammer, Josip Mihaljevic,
David Mönnich, Adriane Gröger, Jan Muzik, Urzula Jelen and Fillippo Ammazzalorso for
being good PhD fellows.
I will thank the people at the Department of Medical physics in Aarhus for welcoming my
visits. Pauliina Wright for your hospitality, humour as well as scientifﬁc input and personal
discussions. Sara Thörnqvist and Maria Thor for their idealism and enthusiasm; good luck
with your PhDs!
I’m also obliged to my other co-authors Àsa Karlsdottir, Odd Harald Odland, Harald Valen,
Randi Ekerold, Dag Clement Johannessen, Lise Bauge Fjellsbø, Hannah Lord (Edinburgh
Cancer Centre) for their contributions.
I want to send my gratitude to the heads of the Department of oncology and medical physics
at Haukeland University Hospital, Olav Mella, Anﬁnn Mehus and Dagﬁnn Brosvik for your
continous support and for providing me with the nescessary infrastructure and comfortable
working conditions. Especially I want to thank Anﬁnn Mehus for including me at the Section
of medical physics, for his caring nature and his ever-lasting ﬁght for getting the best out of
limited resources. Anne Aamelfot and Bjørg Algerøy deserve special thanks for administering
my project and I’m obliged to many of my co-workers at the department for collecting useful
CT data for this project.
As the head of MedViz, Odd Helge Gilja have provided me with the possibility of meeting
a number of people with common interests in medical visualization but different backgrounds.
Thanks to Odd Helge and all MedViz-cooperators for your support, ideas and input and to Elin
Riple for organizing enjoyable meetings.
Last but not least, I want to thank my family. Mamma and Pappa for always listening, en-
couraging and supporting me. My siblings Geir, Kjersti and Bjørn Petter for their positive
view on life and for always being there. My wonderful husband, Marcin and our son, Emil for
showing me what is important in life. You ﬁll my heart with love and happiness every day, and
you are my greatest sources of inspiration.
Summary
The work presented in this thesis explore the potential of pelvic intensity-modulated radiother-
apy (IMRT) to spare the bowel and contributes to the tools to allow for more robust RT plan-
ning for patients with prostate, bladder, rectal and gyneacological cancer. Due to its radiosen-
sitivity and proximity to the pelvic lymph node target, the bowel is often the dose-limiting
organ-at-risk (OAR) in these patients. Furthermore, this organ is difﬁcult to handle in treat-
ment planning because of large amplitude motion and unclear correlation between the planned
dose-volume histogram (DVH) and small bowel adverse effects.
Convential RT planning is based on a computed tomography (CT) scan of the patient ac-
quired about one week prior to treatment start, while RT is administered in daily fractions
over several weeks. Since this image information differs from the exact geometrical conﬁgu-
ration realised during treatment, uncertainties in the delivered dose excist. In the pelvis, organ
motion is the major contributor to these uncertainties. Population-based treatment planning
margins are used around the target volume to make sure the prescribed dose is delivered to the
tumour despite these uncertainties. The transition from conformal to intensity-modulated RT
has emphasized the need for methods to also account for OAR motion.
In this thesis we have investigated the beneﬁt of moving from 3D conformal RT (CRT) to
IMRT for prostate cancer patients who receive RT to the prostate, seminal vesicles and pelvic
lymph nodes. Furthermore, the inﬂuence of organ motion on both techniques was assessed in
order to picture the robustness of todays planning procedures. These studies showed that al-
though IMRT allows for reduced bowel doses compared to CRT, optimization based on the
bowel contour from a single CT scan might result in unacceptable bowel doses in some pa-
tients. These ﬁndings thus emphasized the need for methods to account for bowel motion in
planning of pelvic IMRT.
In this thesis we have therefore also suggested and evaluated two different bowel plan-
ning concepts. The ﬁrst concept was an empirical estimation of a population-based planning
OAR (PRV) margin for the bowel, which was shown to be rather unspeciﬁc because of large
amplitude motion and inter-patient variation. The last part of the thesis therefore focused on
developing a patient-speciﬁc small bowel (SB) planning concept which was based on cover-
age probabilities (CPs). Patient-speciﬁc concepts rely on repeat image information which is
laborious. We therefore aimed at developing a statistical method that made the best out of
the information captured in a few repeat CTs. Compared to commonly used SB planning vol-
umes, the patient-speciﬁc SB PRVs were either similar or better in predicting for SB voxels,
and at the same time they occupied a smaller or similar volume in the patient. They thus show
promise for use in RT planning and might produce DVHs which better represent the delivered
SB dose. Furthermore, the SB CPs generated with this method could be used for pinpointing
conﬂicting regions of target volume and SB and for ﬁnding a compromise for dose to these
regions in robust optimization of IMRT.
To summarize, the current work provides new solutions for handling the bowel in RT
planning which is central for improving pelvic RT by fully exploiting the potential of IMRT.
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Chapter 1
Introduction
About 26 000 norwegians were diagnosed with cancer during 2008 [13]. This corresponds
to an estimated accumulated risk of about 30% of developing cancer at the age of 75 years.
Radiotherapy (RT) is used both for curative as well as palliative treatment of a large frac-
tion of cancer patients, either alone or in combination with other modalities, such as surgery,
chemotherapy, hormonal therapy, anti-angiogenetic drugs or hyperthermia. Survival from can-
cer is highly dependent on cancer site, but overall, RT together with other modalities cure about
65% of all cancer patients [13].
The aim of curative RT is to inactivate all cancer cells, and at the same time minimize
damage to surrounding healthy tissue. Nevertheless, being cured from cancer often comes
with the price of adverse side effects. During and after pelvic RT, such complications are often
related to the bowel. As much as 90% of patients treated with pelvic RT develop permanent
changes in gastrointestinal physiology [2]. In 20-40% of patients, these changes moderately
or severely affect their quality of life [2].
RT has been used in cancer treatment for more than 100 years. The ability to cure the pa-
tient while keeping the risk of side-effects on an acceptable level has changed dramatically
with technological development. Megavoltage linear accelerators (linacs) [95] developed in
the 1930ies are still essential in external-beam photon RT for their penetrating energies. The
development of computed tomography (CT) scanners in 1972 [9] made individual treatment
planning possible by providing information about internal geometry and tissue density. Also
the introduction of the multileaf collimator (MLC) [86] has contributed signiﬁcantly to im-
proving the precision of external beam RT. A MLC consists of many individual leaf pairs
made from a high atomic numbered material like tungsten. It replaced customized lead blocks
to shape the radiation ﬁeld by blocking the beam and thereby shielding surrounding normal
tissue.
The beam’s eye view concept [58] for visualizing the geometry of the contoured tumour
(target volume, TV) and nearby critical organs (organs at risk, OARs) as seen on the CT scan
has also played an important role in RT planning. By applying several beam directions, and
using the MLC to shape the ﬁeld such that it ﬁts to the projection of the TV as seen on the CT
scan through each beam, highly customised dose distributions are produced with 3D conformal
RT (CRT).
The introduction of modulated instead of homogeneous beams through so-called intensity-
modulated RT (IMRT) has further increased the possibilities of conforming the dose distri-
bution to the TV and to spare the OARs by redistributing the dose in the patient. Different
systems are used for delivery of IMRT [1]. With a standard linac, IMRT is delivered from
multiple beam directions by either dynamically moving the MLC leaves during irradiation or
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by delivering the radiation in several steps with different MLC conﬁgurations. The ﬂuence dis-
tributions of the modulated beams are optimized by a computer algorithm based on objectives
given by the planning expert. These objectives directly or indirectly reﬂect the probabilities
of tumour control (TCP) and normal tissue complications (NTCP). Optimal use of IMRT thus
rely on speciﬁc knowledge of the correlation between the planned TV/OAR dose distribution
and TCP/NTCP.
Geometrical uncertainties are a major issue in CRT as well as for IMRT [90]. They occur
because the planning CT information about the position and shape of the TVs and OARs dif-
fers from the exact geometrical conﬁguration during treatment. RT is delivered in fractions,
typically once per day, ﬁve times a week and over several weeks in order to maximise biolog-
ical effect to obtain more cell kill in the tumour than in the surrounding normal tissue. During
this period, typical sources of uncertainties such as differences in the position of the patient
relative to the treatment machine (setup uncertainties) and internal organ motion relative to the
patient’s bony anatomy occur. In pelvic RT, organ motion is extensive and thus the biggest
challenge of these two.
Traditionally, geometrical uncertainties in tumour position has been handled by expanding
the clinical target volume (CTV) by a margin to create the larger planning target volume (PTV)
[39]. By planning using the PTV, the CTV will certainly receive the prescribed dose despite
geometrical uncertainties, given the margin is big enough. Because the knowledge about in-
dividual uncertainties are incomplete prior to treatment, margins are usually population based
[83, 90]. In case of OARs, geometrical uncertainties were usually not considered for planning
of CRT. With the introduction of IMRT, however, the ICRU report no 62 addressed this topic
by introducing the planning OAR volume (PRV) [38]. In analogy to the PTV, the PRV should
account for geometrical uncertainties in OAR position by adding a margin around the organ.
Compared to the PTV, the PRV concept has so far received less attention.
Margin reduction by either reducing uncertainties or by treatment individualisation is an
important topic in RT research. Reduced margins around the CTV lead to smaller high-
dose volumes and consequently less normal-tissue damage which in turn can allow for dose-
escalation to the tumour within the PTV concept. This has driven major developments in
image technology to allow for image-guided RT (IGRT) by tumour localization prior to or
during treatment sessions. IGRT can optionally be used together with adaptive RT (ART) by
methods for individualizing margins based on repeat image information that becomes available
throughout the treatment course [99].
Hard margins through the PTV/PRV concepts are problematic in optimization of IMRT
because they result in overlapping regions of conﬂict [7]. Finding alternative methods to fully
exploit the potential of combining IMRT with IGRT and ART is therefore warranted [1]. Be-
cause these methods rely on repeat volumetric imaging data, image processing has recently
become a relevant topic for RT. It is focused on developing methods for automatic or semi-
automatic segmentation [52], deformable registration and organ motion modelling. Despite
increased availability, repeat image information is still laborious. A challenge in this context
is therefore how to extract useful information about patient-speciﬁc organ motion from few
available samples.
In summary, this Phd-project contributes to improving pelvic RT by adressing: 1)the use
of conventional IMRT compared to CRT to spare the bowel, 2)the inﬂuence of organ motion
on delivered dose and 3)methods to account for bowel motion in planning and evaluation of
pelvic RT. The latter includes methods for calculating bowel PRVs, use of repeat imaging data
for individualization of bowel PRV margins as well as an alternative method for representing
patient-speciﬁc bowel motion.
Chapter 2
Background
For RT of the pelvis in case of prostate, bladder, rectum or gynaecological cancer, the main
motivation for exchanging CRT with IMRT has been to reduce the incidence of gastrointestinal
(GI) adverse effects. This was also our main motivation when introducing IMRT at Hauke-
land University Hospital in September 2005 (Paper I). Patients with locally advanced prostate
cancer were chosen for our IMRT start-up, and consequently the current thesis is based on the
same group of patients, although the developed methods and principles are general.
Locally advanced prostate cancer patients with a risk (estimated to > 15% by [71]) of
lymph node involvment are routinely given irradiation to the proximal pelvic lymph nodes in
addition to the prostate and seminal vesicles in ours as well as other institutions. Irradiation
of pelvic lymph nodes could theoretically sterilise subclinical metastasis and thereby increase
the survival in a subgroup of patients. The costs versus beneﬁts of whole pelvic RT has been
debated for more than two decades for a number of reasons [4, 20, 56, 70, 78, 92]: A) Selecting
the right subgroup of patiens (i.e. with advanced disease but no distant metastasis) is difﬁcult
[20, 71]; B) Identifying which lymph nodes to irradiate is challenging and currently based
on population data which carries the risk of geographical miss [29]; C) Whole pelvic RT is
associated with increased GI adverse effect rates compared to prostate only RT because larger
volumes of small bowel were included in the ﬁeld [20]; D) The pelvic doses are limited to
45-50 Gy to keep the risk of GI complications at an acceptable level and this might not be
sufﬁcient to sterilise the cancer cells [30].
A key to improve treatment outcome of whole pelvic RT is therefore the challenge of
reducing and controlling small bowel related complications. This is challenging because: 1)
knowledge about the radiobiologic mechanisms behind GI adverse effects are limited, and 2)
the mobility of the pelvic organs is considerable, especially for the bowel, such that estimates
of both the applied dose and the dose prescription for optimization are uncertain [35, 36, 45, 62,
67, 77]. The current project has investigated the potential of pelvic IMRT to spare the bowel
as compared to CRT, but also challenges and solutions for better exploiting this potential.
2.1 Potential and challenges of intensity-modulated radiotherapy
The idea and concepts of using modulated instead of homogeneous beams evolved in the
1980s [37]. Different techniques for delivering modulated ﬁelds were developed during mid
1990ies [37]. The ﬁrst IMRT treatment with a dynamically moving conventional MLC was
delivered at the Memorial Sloan-Kettering Cancer Center in New York in 1995 [49]. During
the last decade, IMRT has spread to most RT departments worldwide [93]. This rapid clinical
implementation was driven by numerous planning studies showing the potential of IMRT for
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Figure 2.1: Example of prostate pelvic dose distribution as produced with four-ﬁeld CRT (left)
and seven-ﬁeld IMRT (right). Dose colour wash is from 25 Gy (blue) to approximately 50 Gy
(red). Target volumes are shown in red and bowel in pink. From Paper I.
reducing toxic effects, but happened despite incomplete knowledge about the challenge of
IMRT planning, delivery and quality assurance [93]. In the following, our focus will be on
potential and challenges in IMRT planning with respect to geometrical uncertainties.
Planning of RT is based on our clinical experience. The most intuitive way of using IMRT
is thus to mimic the concept of CRT, but exploiting the technique to better conform the dose
to the PTV (Figure 2.1). Nutting and colleagues were the ﬁrst to demonstrate the advantages
of pelvic IMRT [66]. In a planning study comparing pelvic IMRT and CRT, they showed a
reduction from 18% to 5% in the volume of small bowel receiving more than 45 Gy. Many
other investigators have later conﬁrmed this potential of IMRT to spare the bowel [5, 15, 29,
32, 41, 48, 50, 53, 63, 66, 69, 74, 75, 94].
In order to achieve a good compromise between risk of normal tissue complications and
tumour control, IMRT dose distributions are often tightly tailored to the patient geometry
as imaged on the planning CT scan. One concern has been how organ motion and set-up
uncertainties inﬂuence delivery of such dose distributions. This has also been a topic for CRT
[43, 46, 54], but is even more pertinent with IMRT because tightly tailored dose distributions
tend to be less robust to geometrical uncertainties [7, 40, 98]. Yan and colleagues demonstrated
that prostate IMRT actually required larger PTV margins compared to CRT [98]. Also Löf and
colleagues pointed out that optimized dose distributions could easily loose their advantages
because of uncontrolled changes in set-up, patient geometry, or beam proﬁles [51]. As a
consequence of geometrical uncertainties, ’better’ in planning does not necessarily stay ’better’
in application for all patients.
Geometrical uncertainties are often classiﬁed as systematic or random. Systematic errors
occur if the geometry conﬁguration on the CT scan used for treatment planning deviates from
the mean of the geometries realized throughout the fractionated treatment. Random errors
are variations around this mean deviation occuring with different magnitude at each treatment
fraction. Systematic and random uncertainties have a different impact on the delivered dose
distribution [83, 84]. Common PTV margin recepies are therefore derived from dosimetric
rather than geometrical criteria [83]: i.e. the CTV margin should be big enough to ensure
that the achieved treatment dose and the prescribed dose are in agreement for a large number
of patients. Provided that the margins are adequate, the PTV concept thus ensures robust
treatment plans for the CTV [7].
A competing demand is to control the risk of normal tissue complications. Consequently,
the dose distribution should also be robust for the OARs. To cope with this problem in opti-
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mization of IMRT, ICRU report no 62 introduced the planning OAR volume (PRV) in 1999
[38]. McKenzie and colleagues were the ﬁrst to explore the PRV concept by seeking margin
recipes analogous to a common CTV→ PTV margin approach [57, 91]. They chose a criteria
such that the DVH of the PRV should not underestimate the high-dose volumes in the OAR
in 90% of cases. Such a dosimetric criteria led to different margin recipes depending on the
type, size and position of the OAR relative to the high-dose region. Muren and colleagues
later used an empirical approach to determine margins around the rectum to encompass differ-
ent degrees of rectum motion as seen in a series of repeat CT scans of bladder cancer patients
[60]. In contrast to McKenzie and colleagues, the approach presented by Muren was purely
geometrical. Stroom and Heijmen followed by discussing the limitations of the PRV concept
in a paper where they also investigated a similar but alternative method to McKenzie for deriv-
ing PRV margins around organs with a maximum dose constraint [85]. One limitation of the
PRV concept is that the derived margin recipes are strongly dependent on the case and deﬁni-
tion of max dose, and it is therefore difﬁcult to deﬁne a general recipe in analogy to the target.
Furthermore, it is challenging how to translate dose-volume constraints applied for an OAR to
the much larger PRV. Despite these limitations, Stroom and Heijmen acknowledged that PRVs
can be a useful tool in treatment planning to avoid high doses in proximity to serial OARs.
Planning of IMRT is an optimization process where knowledge- and experience- based
treatment goals of a clinician has to be communicated to the optimization algoritm. The ab-
straction of these goals through the objective function is therefore crucial [1]. The purpose of
the objective function is to control the shape of the dose-volume histogram (DVH), e.g. take
a volume from one bin, reduce the dose and put it in a lower bin. Most commersially avail-
able treatment planning systems use cut-off volumes from the cumulative DVH as objectives
(i.e. the volume receiving more than xGy, Vx). This might not be optimal because: 1) a sin-
gle DVH point does not sufﬁciently control the dose distribution in an organ and 2) multiple
DVH points might be overly restrictive [1]. Biological measures like tumour control probabil-
ity (TCP), normal tissue complication probability (NTCP) and equivalent uniform dose (EUD)
might be better suited because they seek to describe the effect of the whole DVH [1].
The most widely accepted NTCP model is the phenomenological Lyman-Kutcher-Burman
model [10, 44]. At the core of this model lies the ability to map an inhomogenious dose
distribution in an organ to standard conditions of partial organ volume irradiation with an
homogeneous dose, allowing for extrapolation of published dose constraints [21]. Closely
connected to this DVH reduction to an effective partial volume, is the concept of reducing the
DVH to a generalized EUD or effective dose [44, 65]. The generalized EUD relies on a tissue-
speciﬁc parameter k incorporating the volume-effect of the organ in question. It represents
the dose that causes the same radiobiological effect as the inhomogeneous dose distribution if
applied homogeneously to the entire organ.
The direct use of EUD/NTCP or cut-off volumes in optimization of IMRT has stimulated
attempts to establish dose-volume-toxicity relations, also for the bowel [22, 72, 76, 93]. No-
tably, the RT technique can inﬂuence the correlation between planned dose and incidence of
speciﬁc adverse effects, and consequently toxicity relations established with CRT cannot un-
critically be applied in IMRT optimization [80]. EUD models have been shown to be less
prone to such statistical bias caused by correlations of DVH dose bins [82].
Another challenge with establishing dose-volume-toxicity relations is the limited ability of
the planning DVH to represent the actual accumulated dose in an organ throughout the treat-
ment course [24]. Furthermore, dose-volume constraints derived from an OAR DVH cannot
directly be applied to the often much larger PRV [85]. Some investigators have therefore at-
tempted to correlate the PRV DVH to toxicity [22, 61, 76, 88]. The sensitivity and speciﬁcity
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of the PRV is crucial in this context. A PRV is sensitive if it contains a large fraction of voxels
which will be visited by the OAR in future. It is unspeciﬁc if it also contains large volumes
which will never be visited by the OAR. Unspeciﬁc PRVs are problematic in RT planning be-
cause they produce unreliable DVHs, unreliable estimates of evaluators of plan quality, and
difﬁculties to achieve treatment planning dose-volume constraints because of large volumes of
overlap between PRV and PTV.
Planning and delivery of IMRT offers increased degrees of freedom for shaping the dose
distribution which could be exploited beond tailoring the dose to the PTV [37]. One interesting
way of exploiting this freedom is to abandon the PTV/PRV concepts by directly incorporating
geometrical uncertainties of the CTVs and OARs in robust optimization. Robust optimiza-
tion refers to methods aiming to produce dose distributions which result in CTV and OAR
doses which are predictable within an acceptable uncertianty. This is in contrast to PTV/OAR
based optimization which are robust with respect to the CTV only, and to PTV/PRV based
optimization which result in overlapping regions of conﬂict between PTV and PRV.
The most basic robust optimization methods are based on coverage probabilities (CPs)
[83]. A CP matrix is deﬁned on a voxel grid, with each voxel containing the probability of
being occupied by the TV or OAR in question. Baum and colleagues used TV and OAR
CPs as weights for the objective function to compromise the dose in conﬂicting TV/OAR
voxels. Witte and colleagues used a similar concept for optimizing expected TCP and NTCP
[96]. More sophisticated methods replace the common static patient model with a dynamic
patient model for optimizing the dose to moving volume elements of TVs and OARs (see e.g.
[11, 79, 89]). The latter methods are only possible with deformable patient models at hand.
To summarize, IMRT has a great potential for reducing GI toxicity, but this potential might
be jeopardised by geometrical uncertainties. Due to tightly tailored IMRT dose distributions,
the impact of geometrical uncertainties are potentially larger as compared to CRT. Therefore,
methods are required to ensure robust dose distributions both with respect to CTV and OARs.
The PRV concept has been suggested to account for OAR uncertainties in planning of IMRT.
However, it is not straight-forward how to deﬁne clinical useful PRVs. Furthermore, PRVs
do not necessarily lead to robust dose distributions because they often produce overlapping
PTV/PRV regions which are difﬁcult to handle in IMRT optimization. Alternative methods
to PTV/PRV based optimization have been suggested. These are based on methods for organ
motion modeling.
2.2 The bowel as organ-at-risk
The bowel is a radiosensitive organ and pelvic RT therefore often leads to both acute and
chronic changes in gastrointestinal physiology [2]. While acute symptoms often start during
the second week of treatment, chronic symptoms might not become evident until years after
treatment [2]. The most common sympthoms are abdominal pain, diarrhoea, tenesmus (a
feeling of repeatedly needing to open the bowels), incontinence (leakage/soiling), excessive
ﬂatulence and passing blood or mucus when opening the bowels [2]. Severe complications like
ulceration (a sore area that doesn’t heal), obstruction (blockage of the bowel) and perforation
(a hole in the bowel wall) are rare (below 5%) when pelvic doses are limited to 45-50 Gy over
5 weeks [47]. Experience have shown that doses above this limit can increase the risk for
obstruction from 5% to 37% and risk of chronic diarrhoea with up to 40% depending on the
volume of irradiated small bowel [47].
Complications have traditionally been scored according to the lower gastro intestinal
(GI) RTOG/EORTC acute and late radiation morbidity scoring criteria, which grade vari-
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ous radiation-induced complications from 0-4 depending on to their severity as judged by
the physician [17]. More speciﬁc criteria for acute GI complications have been publised by
CTC (common toxicity criteria) [14]. Also methods for patient-graded complications excist
through the LENT SOMA system [73].
The relationships between planned bowel DVHs and Grade  2 GI complications are
unclear. Recent reviews by Fiorino and colleagues and the QUANTEC initiative show that
prospective studies are lacking [23, 42]. Based on results from mostly retrospective studies
[6, 31, 34, 72, 87], QUANTEC recommend DVH constraints for the cut-off volume receiv-
ing  15 Gy (i.e. V15) when contouring speciﬁc bowel loops and V45 when the entire cavity
(i.e. the intestinal cavity, IC) in where the bowel can move is delineated (Figure 2.2) [42]. In
addition, high doses should be minimized. Fiorino and colleagues, explain the correlation be-
tween V15 and acute toxicity with what they call ’geometrical factors’ from use of conformal
techniques [23]. Tho and colleagues and Baglan and colleagues also noted that the effect of
low-dose RT was impossible to isolate from these studies because V15 was correlated to the
high-dose cut-off volumes due to limited DVH variability with conformal techniques [6, 87].
Due to these ﬁndings, Fiorino and colleagues warn against using constraints to limit V15 in
optimisation of IMRT without considering V30−V50 [23].
There are probably many reasons why it is difﬁcult to establish a clear correlation between
the planned bowel DVH and toxicity. Factors and diseases like previous abdominal surgery,
diabetes, hypertension, inﬂammatory bowel disease, HIV, connective-tissue disorders, con-
comitant chemotherapy and smoking can increase the risk of acute and late complications and
are not always corrected for when analysing the data [2]. Furthermore, the RTOG/EORTC
scoring criteria is rather unspeciﬁc because different symptoms are pooled. Even with spe-
ciﬁc sympthoms at hand, ﬁnding the exact causes of these are complex - e.g. as much as 13
different mechanisms reﬂecting changes of different parts of the GI tract lead to diarrhoea [2].
Another potentially important factor leading to a blurring of the correlation between the
planned bowel DVH and toxicity is the excessive mobility of the bowel, which is the topic of
the current thesis [24, 45, 47]. It is a premise of the current work that a clearer correlation
between the planned bowel DVH and toxicity can only be achieved if motion information is
included in the bowel DVH. Studying bowel motion is therefore essential for improving pelvic
RT.
Gallhager and colleagues investigated the volume, distribution and mobility of the small
bowel from orthogonal radiographs [28]. They found that patients with previous ab-
Figure 2.2: Volume rendering of the segmented bowel (solid magenta) and the intestinal cavity
(contour pink).
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dominoperinal resection had a greater volume of less mobile small bowel positioned in the
lower pelvis explaining a higher risk for RT-induced obstruction in these patients. They also
investigated different surgical techniques and patient-positioning methods in order to displace
the small bowel from the pelvic RT treatment ﬁeld and found that a combination of bladder
distention and compression of the anterior abdominal wall in prone position could displace the
small bowel without causing patient discomfort. Such patient position also reduced the inci-
dence of acute diahorrea. The latter ﬁndings have been conﬁrmed by Mak and colleages which
found that an open table top, or a so-called belly-board, shifted the small bowel away from the
ﬁeld and thereby reduced the risk of late small bowel obstruction [55].
Nuyttens and colleagues throughly investigated changes in the position of the small bowel
in a group of rectal patients by measuring distances between bony structure and the nearest
contrast enhanced small bowel loops as seen in 12 patients with 4-7 repeat CT scans each
[67]. They found a considerable standard deviation in small bowel position of 2.7 cm at 5 cm
below the sacral promontory in preoperative patients. In patients with low anterior resection
and abdominoperineal resection (APR), the standard deviations were smaller (1.4 cm and 0.2
cm, respectively). Furthermore, there was a correlation between the most inferior small bowel
position and the bladder volume (except for APR), but no correlations with the anterior and
posterior positions.
Kvinnsland and Muren later studied the impact of bowel motion on conformal bladder RT
DVHs in 10 patients with 6-8 repeat CT scans [45]. They found that in 6 out of the 10 patients,
the volume occupied by the bowel in one scan only was bigger than the volume occupied in
all CT scans. Bowel motion translated into large DVH (and NTCP) uncertainties for individ-
ual patiens, but even larger variability was found between patients. Based on these ﬁndings,
Kvinnsland and Muren accentuated that bowel dose-volume constraints for optimisation of
IMRT shoud be used with care.
Due to the mobility of the bowel and uncertainties in DVH constraints it is not straight-
forward how to include this OAR in optimization of IMRT. Optimization based on the bowel
contour from a single planning CT could potentially lead to an illusionary low dose to the
bowel. Because of large deformations and a complex motion pattern, calculating a bowel PRV
with the McKenzie or Stroom and Heijmen approaches is infeasible. A commonly used PRV
for the bowel is therefore the physical boundary in where the bowel is free to moove, i.e.
the intestinal cavity (IC) (Figure 2.2) [15, 18, 29, 50, 74]. By minimizing the dose to the IC
volume, a low and homogeneous dose is secured to the bowel itself. Although this bowel PRV
is highly sensitive in predicting for future bowel voxels, it is highly unspeciﬁc due to its size.
2.3 Organ motion modelling
In order to ﬁnd alternative methods to account for bowel motion in optimization of IMRT,
various organ motion modelling methods and their applicability for the bowel are discussed in
the following. Modelling of organ motion uncertainties is one of the main focus areas in RT
research. A number of relevant recipes have been published [7, 19, 25, 26, 33, 81, 83, 97].
Some of these neglect deformations by assuming rigid body motion [19, 83]. This would
probably not be valid for the bowel where peristalsis waves displace the bowel wall with a
mean amplitude of around 7 mm occuring about 11 times per minute [27].
Hoogeman and colleagues simulated rectum deformations by stochastic sampling of a set
of shape and shape-change parameters deﬁned on a slice-by-slice basis from the probability
distributions of these parameters as estimated in a group of reference patients [33]. However, a
slice-by-slice based approach would not be feasible for the bowel because it can move more or
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less freely within the pelvis, also in the cranio-caudal direction. Both of the above-mentioned
methods are examples of using population-statistics to estimate uncertainties in organ position
or shape. Adaptive approaches, on the other hand, seek to include patient characteristics by
measuring individual uncertainties.
Yan and colleagues have shown that the convex hull (union) of the CTV (i.e. prostate and
seminal vesicles) from a few repeat CT scans capture a large degree of organ motion and can
be used to construct a much smaller PTV than a single CTV pluss a population based margin,
while maintaining the same dosimetric criterion [98]. By including more planning CTs, the
systematic uncertainty is reduced in a simple manner. More sophistically, Yan and colleagues
also modelled individual organ shape changes from repeat CT scans by using a biomechanical
ﬁnite element model driven by user-placed ﬁducial landmarks on the organ surface to gener-
ate groups of intermediate organ shapes by interpolation between the surface point positions
in the measured geometries [97]. Söhn and colleagues [81] reﬁned this approach by using
a point distribution model to reduce the large dimensionality of the geometrical information
from repeat CTs into a few statistical parameters which describe correlated displacement of
the organ surface points around the mean organ shape. Others have presented different ap-
proaches also acting on corresponding points [25, 26]. Because it is impossible to distinguish
between bowel segments in CT images and hence to deﬁne ﬁducial landmarks on the bowel
wall, no point-correspondence model can be made for this organ. This is the major challenge
in modelling bowel motion and is one of the main reasons why this organ is treated seperately
in the present work.
An alternative and common way to represent organ motion is by coverage probabilities
(CPs). CPs were ﬁrst introduced by Stroom and colleagues [83] who used it to model the
impact of systematic uncertainties on the CTV DVH and to establish a PTV margin recipe.
Because the CP matrix is a static patient model, it doesn’t rely on point correspondence models.
Coverage probabilities were thus a natural choice for representing bowel motion in the current
work. Baum and colleagues sampled CPs by estimating the relative frequency of coverage
of an organ as outlined in multiple CT scans [7]. This approach have been demonstrated for
prostate, rectum and bladder, but is in principle also applicable for the bowel. However, when
applied to organs with large amplitude movements the approach converges very slowly to the
true CP matrix. Consequently, the CP matrix might contain holes where the optimization
algorithm is free to deposit high doses when based on a few CT scans [7].
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Chapter 3
Aims of the project
The aim of this thesis was to study the potential of conventional pelvic IMRT to spare the
bowel and to develop methods for further exploiting this potential. Speciﬁcally, we aimed at:
• Comparing IMRT to CRT in locally advanced prostate cancer patients (Paper I and II).
• Studying the inﬂuence of organ motion on the planned dose distributions in treatment of
locally advanced prostate cancer patients (Paper II).
• Deﬁning clinical useful bowel PRVs (Paper III and IV).
• Developing a statistical method for making the best use of scarce imaging data to gen-
erate patient-speciﬁc small bowel PRVs based on coverage probabilities (Paper IV).
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Chapter 4
Materials and methods
This chapter gives an overview of the applied patient materials as well as the methods which
were used and developed to fulﬁl the aims of the project. Further details can be found in the
corresponding papers (Papers I-IV).
4.1 Patient materials
The methods developed in the project are relevant for all patients receiving pelvic radiotherapy.
That includes patients with prostate, bladder, rectum and gynaecological cancer where the
lymph nodes are part of the target volume. However, the studies were mainly performed on
patients with locally advanced prostate cancer who received pelvic external beam radiotherapy
at Haukeland University Hospital. These patients had two clinical target volumes (CTVs)
deﬁned. Both CTVs consisted of the prostate and seminal vesicles, while CTV11 also included
the relevant lymph nodes. Two planning target volumes (PTVs) were constructed by adding
margins around the CTVs. A 15 mm margin was used around the prostate and seminal vesicles
except towards the rectum, where a 10 mm margin was used. For the lymph node volume, an
isotropic 10 mm margin was used.
In order to include information about organ motion, two different datasets of patients with
CT scans acquired once or twice a week during the treatment period were used. One of these
datasets consisted of the CT data of totally 20 male bladder cancer patients which had 6-
9 CT scans each. Out of these, 14 patients were treated at Haukeland University Hospital
in the period from January 2000 to October 2001 and 6 patients were treated at Edinburgh
Cancer Centre during 2003. The other dataset consisted of 3 prostate cancer patients treated
at Haukeland University Hospital during May/June 2007. The CT data of these three patients
were taken from a dataset of totally 40 patients with 10-11 CT scans each which was collected
within the present project for use in current and future studies about bowel motion.
In some of these datasets, one bowel volume consisting of both the large and small bowel
was contoured, while in the other dataset the large and small bowel were contoured seperately.
When using the term bowel we therefore refer to the volume containing both the large bowel
(LB) and the small bowel (SB).
1This ’outdated’ nomenclature was chosen for concictency with Papers I-II, despite the recent ICRU 83 rec-
ommendations [40].
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4.2 Conformal vs. intensity-modulated prostate pelvic RT
Two of the studies were planning studies where we compared CRT with intensity-modulated
prostate pelvic RT. The procedures for treatment planning and evaluation are outlined in the
following and more details can be found in Papers I-II. One CT scan of the patient was used
for treatment planning.
4.2.1 Planning of conformal and intensity-modulated prostate pelvic RT
CRT planning of prostate pelvic radiotherapy was performed according to the routine practice
at Haukeland University Hospital as until September 2005. The treatment of these patients
then consisted of two phases; ﬁrst, 50 Gy was delievered in 25 fractions to the prostate, sem-
inal vesicles and relevant lymph nodes with margins (i.e. to PTV1), and second, 20 Gy was
delivered to the prostate and seminal vesicles with margins (i.e. to PTV2) in 10 fractions. Both
CRT plans consisted of four beams with gantry angles of 0◦, 90◦, 180◦and 270◦. A PTV dose
variation within 95% and 107% of the prescribed dose was aimed for, but a minimal point
dose of 90% of the prescribed dose was accepted in the posterior part of the PTV to avoid an
unacceptably high rectum dose.
IMRT planning of prostate pelvic radiotherapy was performed using the treatment planning
system available at Haukeland University Hospital (Eclipse, Varian Medical Systems, Palo
Alto, CA)). This planning system uses dose-volume objectives with priorities for both the
PTV and OARs. As for CRT these patients were still treated in two phases, but with the ﬁrst
phase of treatment (up to 50 Gy) delivered with IMRT. In the initial phase after moving from
CRT to IMRT, the objectives were based on what could be obtained with CRT for the patient
in question. With IMRT, we aimed at reducing the volume of rectum, bladder and bowel
receiving more than 30, 40 and 50 Gy by 25%, 25% and 50% compared to CRT, respectively.
The IMRT plans consisted of seven coplanar beams with gantry angles of 0◦, 51◦, 103◦, 154◦,
206◦, 257◦, and 309◦. During the optimization, the highest priority was given to the minimal
dose criterion of 95% of prescribed dose to the PTV.
No attempt was made to account for OAR motion neither for the CRT plans nor for the
IMRT plans.
4.2.2 Evaluation of conformal and intensity-modulated dose distributions
To compare the treatment plans, we ﬁrst reduced the 3D dose distribution to dose-volume
histograms (DVHs), both for the PTVs and the most relevant OARs (i.e. bowel, bladder, and
rectum in case of Paper I and II, as well as the penile bulb, hip joints, and hip joint muscles in
case of Paper I). For the OARs, dose cut-off volumes from 20 Gy to 70 Gy in intervals of 10
Gy were compared in Paper I. In Paper II, we only compared the dose distributions resulting
from the ﬁrst phase of the treatment (i.e. up to 50 Gy).
Also the generalized equivalent uniform dose (gEUD) [65] was used (in Paper II) to com-
pare bowel, bladder and rectum doses. Normally, the gEUD is calculated relative to the volume
of the whole organ, but in case of bowel, only the part of the bowel within the lower pelvis
was contoured. We therefore extended the gEUD concept of Niemierko to calculate the gEUD
relative to an absolute reference volume (Vre f ):
gEUD= (
1
Vre f
∑
i
νiDki )
1
k (4.1)
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where (νi,Dki ) denotes the ith bin of the differential DVH, and k is associated with the volume
effect of the organ considered. For the bowel, we used a Vre f equal to 200 cm3 and a volume
effect parameter k = 4, while for the rectum and bladder, we calculated gEUD relatively to the
whole organ volume with k = 12 and 8, respectively [82]. A k = 12 practically only considers
the volume elements receiving≥ 80% of the maximum dose (i.e. a small volume effect), while
a reduction with k = 4 would also consider the volumes receiving intermediate doses (> 50%)
but would weight these against greater dose volumes (i.e. a larger volume effect).
4.2.3 Inﬂuence of organ motion on CRT vs. IMRT
In order to investigate the inﬂuence of organ motion on CRT compared to IMRT in Paper II,
we used the dataset of 20 male patients with 6-9 CT scans each to estimate the mean treatment
bowel, bladder and rectum gEUDs and dose cut-off volumes. The dose distribution was not
recalculated on each of the treatment CT scans, because only the contoured bowel, bladder
and rectum volumes were available (and not the CT scans themselves). The gEUDs calculated
from the planning DVHs were denoted gEUDplan and the mean of the gEUDs resulting from
the CT scans acquired during treatment were denoted gEUDtreat . Correspondingly, the dose
cut-off volumes were denoted Vxplan and Vxtreat , where x ∈ [25, 30, 35, 40, 45, 50] Gy was
the cut-off dose. In order to investigate if IMRT was superior to CRT also when considering
OAR motion, we compared gEUDtreat and Vxtreat from the CRT dose distribution with the
IMRT dose distribution. We also compared gEUDplan with gEUDtreat and Vxplan with Vxtreat
for both CRT and IMRT to see how robust the dose distributions were towards organ motion.
4.2.4 Statistics
All statistical tests were performed using Statistical Package for Social Sciences, version 13.0
(SPSS, Chicago, IL). All p-values were derived from two-sided tests and a p-value below 0.05
was considered statistically signiﬁcant. In most cases the paired t-test was used, but in cases
where the paired differences of the test variables did not follow a normal distribution, the
Wilcoxon test was applied.
4.3 Methods to account for bowel motion for use in radiotherapy
Two different methods to account for bowel motion was developed and tested in the project.
The ﬁrst method (described in Paper III) was a quantiﬁcation of a population based PRV mar-
gin for the bowel, based on the recommedations from ICRU report no 62 [38]. The second
method (described in Paper IV) was an estimation of patient-speciﬁc small bowel wall (SBW)
coverage probabilities (CPs) and PRVs from a few patient-speciﬁc CT scans.
4.3.1 Quantiﬁcation and evaluation of a population-based PRV margin for the bowel
To quantiﬁy a population-based PRV margin for the bowel we used the dataset of 20 male pa-
tients with 6-9 CT scans each. Isotropic margins of 5-30 mm in intervals of 5 mm were added
to the bowel contour of the planning CT scan by using the 3D margin tool of the Eclipse treat-
ment planning system. The bowel contours from the additional CT scans were used to create
so-called location probability maps, where each voxel was assigned an estimated probabil-
ity of containing the bowel of 12.5%-100% in intervals of 12.5% (Figure 4.1). The fraction
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of patients for which a given PRV encompassed 85%, 90% and 95% of the different loca-
tion probability volumes was derived. Also the average volume fraction of the PRVs with no
probability of containing the bowel was investigated to get a measure of the speciﬁcity of the
PRV.
4.3.2 A method to estimate patient-speciﬁc small bowel coverage probabilities and
PRVs
In paper IV we developed a statistical method to estimate patient-speciﬁc SB PRVs by exploit-
ing the information about individual SB motion captured in a number n of repeat CT scans.
The PRVs were calculated from a CP matrix by thresholding. Voxels with a CP-value above
the threshold were included in the PRV and voxels with a lower CP-value than the threshold
were excluded from the PRV. The procedure for calculating SB CPs is illustrated in Figure 4.2.
Baum and colleagues modelled CPs by recording the relative frequency of coverage [7].
Our approach is designed to converge towards the Baum approach when the number of CT
scans approaches inﬁnity, but extended the concept by adding a soft margin to capture the
additional uncertainty in SB position with few CT scans. This should prevent the CP matrix
from containing any holes, i.e. voxels which were assigned a CP equal to zero, but still had a
risk of being occupied by the SB in future.
In order to estimate the ’soft margin’ we considered the variability in SBW position be-
tween the n CT scans of an individual patient. Peristaltic waves of the SB, occuring about
11 times per minute and displacing the SBW with an average amplitude of 7 mm represent
one of two main effects of SB motion [27]. Another main effect is large amplitude shifts of
parts of the SBW or SB due to e.g. change in content and bladder ﬁlling. We assumed that
patient-speciﬁc patterns of large amplitude motion or stability in the SBW will become evi-
dent in the accumulation of CT scans. By adding a soft margin around the SBW instances, we
further assumed that all voxels with the same distance away from the SBW as seen in one or
more CT-scans had approximately the same probability of being visited by the SBW in future.
The soft margin was estimated as a function of the closest distance to any known SBW
voxel. Therefore, patients showing a large variability in SBW position got a broader esti-
mated soft margin than patients showing less variability in SBW position. As the number of
included CT scans increased, the soft margin got tighter (Figure 4.3). If the number of CT
scans approaches inﬁnity, the margin width would approach zero.
The CP matrix was calculated by ﬁrst smearing out each of the SBWs with the soft mar-
gin and later adding up the voxels of the smeared out matrices and multiply with a volume-
preserving normalizing constant.
Figure 4.1: Example of bowel location probability map from repeat CTs as well as the planning
bowel contour B0 shown in solid white and B0+10 mm margin shown in dotted white.
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Figure 4.2: Illustration of the procedure for calculating small bowel coverage probabilities
(CPs) from n= 3 CT scans.
4.3.3 Evaluation of patient-speciﬁc SB PRVs
To test the method we applied it on three patients with different degrees of SB motion. Max-
imum ﬁve CT scans was considered clinically feasible, and consequently the PRVs generated
from 2-5 CT-scans were evaluated by their sensitivity and speciﬁcity with respect to the PRVs
from all 10-11 repeat CT-scans. The effect of different CP-threholds and its impact on sensitiv-
ity and speciﬁcity of the generated PRVs was studied. Based on the sensitivity and speciﬁcity
study, two thresholds were chosen for comparison of the current concept with conventional
methods; CP=0.005 (i.e. generous patient-speciﬁc PRVs) and CP=0.03 (i.e. tight patient-
speciﬁc PRVs) (Figure 4.4). These were compared to an intestinal cavity (IC) approach a a
population based PRV approach of 10mm and 30mm isotropic planning margins. Sensitivity
was compared by estimating the overlap between the planning volume in question and ran-
domly chosen independent SB- /SBW volumes, while speciﬁcity was measured by comparing
relative planning volumes (i.e. the volume relative to a boundary composed from the hull of
all available ICs of the patient in question).
4.3.4 Future application of small bowel PRVs and coverage probabilities
In principle, the patient-speciﬁc small bowel PRVs can be included into any treatment planning
system by writing the coordinates to a DICOM RS structure ﬁle. Because the PRV volume
differs from the SB volume, dose-volume or EUD constraints for the SB cannot be transferred
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Figure 4.3: Example of estimated soft margins around the SBW for one patient when including
n= 2−9 CT scans. If the number of CT scans approaches inﬁnity, the margin would approach
zero.
directly to the PRV [85]. We suggest to weight the PRV DVH by a factorVtotSB /V
tot
PRV , reﬂecting
a homogeneous SB coverage probability distribution within the PRV.
The SB coverage probability matrix can alternatively be used directly in optimization as
described by Baum and colleagues [7]. In the treatment planning system Hyperion, developed
at the University of Tübingen, organ speciﬁc coverage probabilities are used as an importance
weight to each TV and OAR voxel for the objective functions during optimization. Coverage
probabilities of the SB can thus be used in combination with the Baum approach to pinpoint
conﬂicting regions of SB and TV and to ﬁnd a compromise for dose to these regions. See Fig-
ure 4.5 for an example of using SB CPs in optimisation of prostate pelvic IMRT in Hyperion.
Furthermore, the SB CPs could be used in evaluation of IMRT by weighting the DVH. The
differential volume receiving a dose in the interval ΔD, pV (ΔD), would then be calculated as:
pV (ΔD) = v
N
∑
i,D(i)∈ΔD
̂cp(i), (4.2)
where v denotes the absolute voxel volume, N is the total number of voxels, and̂cp(i) is the
coverage probability of voxel i.
It should be mentoned that the current work (Paper IV) focused on the development and
testing of the method rather than application. However, the areas of application described here
Figure 4.4: Example of PRVs created from 3 CT scans and overlaid on the CP matrix created
from all 11 available CTs. A generous PRV (green) was obtained by applying a CP threshold
of 0.005, while a tighter PRV (red) was obtained by applying a CP threshold of 0.03.
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Figure 4.5: Example of using SB CPs in combination with the Baum approach for optimization
of prostate pelvic IMRT in Hyperion with three input CTs.
served as an objective while developing the method and furthermore lays the fundation for
future work.
20 Materials and methods
Chapter 5
Summary of results
5.1 Paper I
The ﬁrst paper was a description of our procedures for planning and veriﬁcation of prostate
pelvic IMRT as well as a presentation of our ﬁrst clinical experiences after moving from CRT
to IMRT for this patient group. A DVH comparison of CRT with IMRT in 15 patients showed
that moving from conformal to intensity-modulated RT considerably reduced irradiation of
bowel, bladder and rectum. At the same time, IMRT improved the target coverage. Also the
initial clinical outcome results were promising. With these results, we were in line with others
who have emphasized the superiority of the IMRT dose distribution compared to the dose
distribution produced with CRT for this group of patients. However, none of these studies
considered that the large mobility of the relevant OARs (i.e. the bowel, rectum and bladder)
could jeopardize the superior normal tissue sparing obtained with IMRT.
5.2 Paper II
In this paper we investigated the inﬂuence of OAR motion on prostate pelvic CRT and IMRT
and showed that the examined IMRT approach still allowed for reduced doses to the OARs
compared to CRT even when accounting for internal organ motion. Internal organ motion
made all dose volume parameters worse compared to the planned dose volume parameters
both for CRT and IMRT. This could potentially translate into violation of dose constraints and
showed that neither the CRT nor the IMRT dose distributions were especially robust towards
OAR motion. Notably, the gEUD was less sensitive towards bowel motion than were the
volume parameters. However, large differences between the planned and estimated treatment
gEUD were found for the bowel in some of the patients. This means that planning based on
one bowel contour can easily translate into greater delivered than planned bowel doses.
5.3 Paper III
This paper was a quantiﬁcation of an empirical population-based PRV margin for the bowel.
We showed that isotropic margins of up to 30 mm were required to account for all bowel
motion in 90% of the patients. Smaller margins of 5-10 mm were shown to encompass the
major part of volumes which had a probability of bowel occupancy of  75% in 90% of
the patients. Population-based PRV margins for the bowel were further shown to be highly
unspeciﬁc, meaning that they also included large volumes with no bowel occupancy at all.
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With a 30 mm margin, 58-84% of the PRV had no bowel occupancy in the treatment CT scans.
With these results we showed that more sophisticated methods are required to account for
bowel motion. Due to large differences between patients, individually-based methods should
be investigated.
5.4 Paper IV
In this last paper we presented a new method to estimate patient-speciﬁc small bowel PRVs
based on a few CT scans. The sensitivity and speciﬁcity depended on the number of CT
scans and the applied CP-threshold. The best trade-off between sensitivity and speciﬁcity was
obtained at a threshold of 0.03. With this threshold and three CT scans, an average sensitivity
of 94-96% and speciﬁcity of 86-97% was obtained in the three studied patients. Using a CP-
threshold greater than 0.05 resulted in a dramatic drop in sensitivity. It was shown that three or
more CT scans were required to secure a good representation of the patient-speciﬁc variability
in SBW position. As compared to conventional planning volumes, the patient-speciﬁc PRVs
were either similar or better in predicting for SB voxels, and at the same time they occupied a
smaller or similar volume in the patient.
Chapter 6
Discussion
The work presented in this thesis aimed to contribute to the tools to allow for more robust
treatment planning of pelvic RT for patients with prostate cancer, rectum cancer, bladder can-
cer and gyneacological cancer. The beneﬁt of moving from CRT to IMRT for prostate cancer
patients who receive RT to the prostate, seminal vesicles and pelvic lymph nodes was investi-
gated and the inﬂuence of organ motion on both techniques was assessed in order to quantify
the robustness of todays planning procedures. These studies emphasized the need for meth-
ods to account for bowel motion in planning of pelvic RT. In the last part of this thesis, we
therefore presented and evaluated two different concepts to account for such motion. The ﬁrst
concept was an empirical estimation of a population-based planning organ-at-risk (PRV) mar-
gin for the bowel, and the second concept was a method to estimate patient-speciﬁc SB CPs
and PRVs.
Our work, in line with others [5, 15, 29, 32, 41, 48, 50, 53, 63, 66, 69, 74, 75, 94], has shown
that the use of IMRT for prostate pelvic RT better conforms the dose to the PTV and therefore
reduces the doses to the major OARs (bowel, bladder and rectum) while at the same time
improving target coverage. Nutting and colleagues were the ﬁrst to investigate the potential
beneﬁt of using IMRT in stead of CRT to treat the pelvic lymph nodes. They reported a
reduction from 18% to 5% of the bowel receiving more than 45 Gy (V45) when replacing CRT
with IMRT [66]. However, IMRT redistributes the dose in the patients such that a reduction
in the bowel V45 has to be repaid by greater volumes receiving lower doses. It is therefore
difﬁcult to conclude about the clinical beneﬁt of moving from CRT to IMRT for these patients
based on single CT planning studies.
Knowledge about the correlation between bowel dose-volume parameters and the risk of
GI adverse effects, especially diarrhea, is unclear. Although many studies have recognized
adverse effects from irradiation of the bowel, only a few studies have reported a correlation
with dose-volume data [6, 16, 22, 31, 34, 42, 68, 72, 87]. Furthermore, these ﬁndings were
ambigious with some studies reporting V45 to be the predictive cut-off volume and others
reporting lower dose cut-off volumes, especially V15, to give the best correlation with acute
diarrhea. Divergent deﬁnitions of the bowel (i.e. bowel, SB or LB loops vs. IC) and use of
absolute vs. relative DVHs also make comparisons between these studies difﬁcult. It should
be noted that consideration of absolute volumes are more relevant than relative volumes for
the bowel because only parts of the organ is delineated. The recent review by QUANTEC
recommended different DVH constraints depending on the deﬁnition of bowel (i.e. V15 in case
of bowel loops andV45 in case of IC). Although OAR DVHs and PRV DVHs are expected to be
different [85], it is difﬁcult to understand how QUANTEC could conclude on fundamentally
different bowel vs. IC constraints bearing in mind the possibility of correlation between low
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and high dose bins with CRT DVHs [6, 23, 80, 82, 87]. A recent study by Perna and colleagues
of postoperative pelvic IMRT further question the QUANTEC-conclusion of the importance
of V15 [68]. They found V45 to be the predictive cut-off volume even when investigating the
correlation between acute toxicity and the DVH of bowel loops. No correlation was found for
V15.
During optimization we used dose-volume objectives at 30, 40 and 50 Gy aiming at
controlling the intermediate and high bowel doses. Our calculations of generalized EUD
was based mainly on the ﬁndings by Roeske and colleagues on Grade 2 acute diarrhoea
(k = 3.2± 1.1 and threshold volume of 195 cm3) [72]. We used a volume-parameter k = 4
and a reference volume of 200 cm3, which considered the bowel volumes receiving intermedi-
ate and high doses (i.e. V25−V50, with more weight on high doses). Our results thus rely on
the assupmtion of V45 being of higher importance than V15.
Although SB motion has been pointed out as one of the reasons to why a limited correla-
tion has been found between dose volume parameters for the SB and adverse GI complications
[23, 24, 45, 47], little has been done to investigate the inﬂuence of bowel motion on the deliv-
ered dose distribution and to account for bowel motion in RT planning [45, 67, 77]. Nuyttens
and colleagues reported considerable variation in SB position during RT in patients with rec-
tal cancer treated with preoperative and postoperative RT [67]. Muren and colleages found
large variations in bowel volume between patients, especially in the lower pelvis (below the
promontory) [62]. Kvinnsland and Muren later investigated the impact of pelvic organ motion
on DVHs in ten bladder cancer patients treated with CRT and found that bowel motion cause
large uncertainties in the DVHs for the individual patients [45].
In the present work, we have shown that despite the uncertainties in the bowel DVH due
to organ motion, prostate pelvic IMRT optimized using one bowel contour still allows for
reduction in bowel gEUD compared to CRT. This has also been conﬁrmed by clinical studies
showing reduced GI complications when moving from CRT to IMRT (see the recent review
by Veldeman [93]). The advantage of IMRT over CRT was mainly due to a reduction in the
total volume receiving≥ 45Gy with IMRT. Bowel motion thus resulted in a signiﬁcantly larger
treatment V45 than planned with CRT. With IMRT, the biggest differences between planning
and treatment were seen for lower dose cut-off volumes. In terms of gEUD, IMRT did not turn
out to be less robust than CRT. Notably, the gEUDs were less sensitive to organ motion than
the cut-off volumes. Because these are also less sensitive to correlation between DVH dose
bins [80, 82], they should be prefferred over cut-off volumes in optimization and evaluation.
In this study (Paper II), organ motion was included by averaging gEUDs. Hoogeman and
colleagues have shown that this is a good way of estimating rectal wall EUDs [33]. Also Baum
and colleagues used average EUDs for estimating the effect of organ motion [7]. Methods for
accumulation of dose have become more available over the last years and should be preferred
over averaged EUDs when available and applicable [64, 97].
Although the inﬂuence of organ motion was different for CRT and IMRT, it made dose
metrics worse. In some patients this translated into much higher bowel doses than planned for,
and treatment planning based on single CT PTV/OARs is therefore not optimal. Sanguineti
and colleagues also found increased bowel V45 during treatment in 8 out of 9 patients when
optimizing whole pelvic prostate IMRT based on the bowel as seen on a single planning CT
[77]. This shows that alternative methods accounting for bowel motion are needed. Sanguineti
and colleagues further compared three strategies to delineate the bowel for use in optimization
of prostate pelvic IMRT: one bowel contour, one bowel contour + a 10 mm isotropic margin
and the IC volume [77]. The isotropic 10 mm margin was based on our study, where it was
shown to be sufﬁcient to cover 90% of the volume occupied by the bowel in more than half of
25
the CT scans in 90% of the patients (Paper III). Sanguineti and colleagues found bowel+10mm
to be the most sensitive PRV among these, but also the one with the largest volume. These
ﬁndings were probably inﬂuenced by the fact that the PRV was not restricted to within the IC.
When applied in optimization, both the bowel+10mm and IC volumes produced dose distribu-
tions resulting in a lower bowelV45 at treatment as compared to optimization on a single bowel
volume [77]. Interestingly, the patient-speciﬁc variation in V45 between repeat CT scans were
similar for all three approaches.
The development of a method for generating patient-speciﬁc small bowel PRVs in the
present work (Paper IV) was motivated by eliminating the large variability in bowel motion be-
tween patients [45, 62, 67, 77, 98]. When compared to population based PRVs (i.e. SB+10mm,
IC and SB+30mm), the patient-speciﬁc PRVs were either similar or better in predicting for SB
and SBW voxels, and at the same time they occupied a smaller or similar volume in the pa-
tient. Importantly, they were also more robust in the meaning of being less dependent on the
motion pattern of the patient in question. However, patient-speciﬁc PRVs are more resource-
intensive because they require more than one CT scan as well as the SB and IC contours from
these CTs. In cases where target coverage is easily obtained with the IC approach, using the
patient-speciﬁc SB PRV approach instead might not be worth the additional workload. Nev-
ertheless, using the patient-speciﬁc SB PRV instead of the IC volume increases the degrees of
freedom for the optimizer which is essential in situations where for instance a dose escalation
to the pelvic lymph nodes is warranted [8, 59].
Both PRV concepts investigated in the current project (Paper III and IV) are based purely
on geometrical considerations. When ICRU suggested the use of margins around OARs, the
PRV was deﬁned in analogy to the PTV, but without any given dosimetric criteria [38]. Stroom
and Heijmen pointed out the difﬁculty of deﬁning a general PRV recipe based on a maximum
dose constraint [85], while McKenzie suggested different recepies depending on the char-
acteristics of the dose distribution [57]. IMRT dose distributions are even more difﬁcult to
characterize compared to CRT. In contrast to McKenzie and colleagues and Stroom and Heij-
men, Muren and colleagues suggested to quantify rectum PRV margins based on organ motion
as seen in repeat CT scans [60]. The advantage of the latter approach is that it included data
on deformation, the disadvantage is that these ﬁndings are difﬁcult to generalize. Both Stroom
and Heijmen and Muren and colleagues discussed the problem of transferring dose-volume
constraints applied for an OAR to the usually much bigger PRV [60, 85]. Muren and col-
leagues later studied the association between their rectal PRV DVHs and acute and late GI
side effects [61, 88]. For the bowel, several studies have tried to correlate the IC DVH to GI
side effects [22, 76]. Because our patient-speciﬁc SB PRVs are smaller than the IC volume
and at the same time has a comparable sensitivity in predicting future SB voxels, it is likely
that patient-speciﬁc SB PRV DVHs would better represent the delivered bowel dose than the
IC DVH.
All DVHs used for RT planning are surrogates of the real accumulated dose delivered to
an OAR during the course of radiotherapy, and constraints used for optimization are deﬁned
based on our clinical experiences with these surrogates. Therefore, one could argue that as
long as the same surrogate DVH is used for planning and evaluation, it should not matter
whether this surrogate is derived from a PRV, the organ volume from the snap-shot of a CT or
other representations of this organ such as the organ hull from more than one planning CT or
the IC volume in case of the bowel. On the other hand, the amount of bowel within the lower
pelvis may be of importance, and this information is lost when replacing the bowel volume
with a PRV. A simple approach to retain this information is to weight the absolute PRV DVH
by a factor VtotB /V
tot
PRV . By doing this, patients with a large amount of bowel within the PRV
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would be differentiated from patients with less bowel.
Another drawback of PRVs is that they are ’binary’-approaches in the way that a voxel is
either deﬁned as belonging to the PRV (value 1) or not (value 0). This poses a problem in
optimization of IMRT, where one has to compromise the dose to regions where the TV and
OAR overlap. Adding a margin around both the TVs and the OARs naturally leads to larger
regions-of-conﬂict for the optimizer. Baum and colleagues suggested using CPs rather than
static 0/1-volumes as a tool to handle such regions-of-conﬂict [7] . An alternative to using
PRVs is therefore to directly use the CP matrix in robust optimization of IMRT. Also with CP-
based optimization there is a question of how to transfer known dose-volume constraints. The
most intuitive way of doing it would be to weight the contribution of each voxel with the CP. If
the CP matrix reﬂected systematic uncertainties the CP weighted DVH would then represent
the delivered dose in an organ [83], but when reﬂecting random motion the usefulness of a CP
weighted DVH is questionable.
This deﬁciency of CPs occur because dose is evaluated in dose space of the static patient
model, ignoring how different parts of the organ move in relation to one another [81]. Igno-
rance of correlated motion (both within an organ and between organs) with the static patient
model, further constrains the possibilities for dealing with conﬂicting TV and OAR regions
because the probability clouds might have common regions. Sobotta and colleagues recently
published a robust optimization method based upon statistical theory (R.O.B.U.S.T) which
solves this problem by optimization of distributions of treatment outcome incorporating corre-
lation in geometrical shifts [79]. As this method is based upon point-correspondence models
which are extremely hard to establish for the SB, CP based optimization most likely remain
the best solution for this OAR. However, with recent development in deformable registration
(e.g. [12]), it might be possible to establish such models of the sigmoidum and large bowel
despite large amplitude motion.
Chapter 7
Conclusions
This PhD project has shown that use of conventional IMRT for pelvic RT in prostate can-
cer patients better spares the bowel compared to CRT, while at the same time improving target
coverage. The advantage of IMRT over CRT was maintained under inﬂuence of bowel motion.
However, bowel motion made dose metrics worse both for IMRT and CRT and optimization
based on a single bowel contour was not optimal for all patients. Therefore, methods account-
ing for bowel motion are needed to better exploit the potential of IMRT to spare the bowel.
Two planning organ-at-risk (PRV) concepts for the bowel were developed and evaluated
in this PhD. The ﬁrst concept was an empirical estimation of a population-based bowel PRV.
Due to large inter-patient variation, this method produced PRVs which were very large when
accounting for all bowel motion in a large fraction of patients. Alternatively, a tighter mar-
gin could be used to produce a smaller and thus a more speciﬁc PRV, but at the expence of a
poorer sensitivity in predicting for future bowel voxels. The second concept was a patient-
speciﬁc small bowel PRV based on a statistical method for estimating coverage probabil-
ity (CP) maps from repeat CT scans. By removing intra-patient variability, more speciﬁc
PRVs could be obtained without compromising sensitivity. The speciﬁcity/sensitivity of these
patient-speciﬁc PRVs was tunable by the CP threshold. Importantly, they were more robust
towards patient-speciﬁc small bowel motion patterns. Patient-speciﬁc small bowel PRVs thus
provide a promising tool for use in PTV/PRV based IMRT optimization.
Finally, the method developed in this PhD project further has laid the fundation for CP-
based robust optimization of pelvic IMRT with the small bowel as OAR.
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Chapter 8
Future perspectives
A natural ﬁrst step beyond this Phd project will be to investigate the use of patient-speciﬁc
small bowel PRVs and CPs in robust optimization of pelvic IMRT. We hypothesise that these
concepts allow for more robust treatment planning compared to the IC approach. In an IMRT
planning study we will therefore compare 1) the PTV + IC approach, 2) the PTV + patient-
speciﬁc PRV approach and 3) the CPTV + CPSBW approach. The coverage probability matrix
for the target volume (CPTV ) and for the other relevant OARs could for instance be obtained
from the method presented by Baum and colleagues [7].
Evaluation of the estimated CP-values in Paper IV is difﬁcult without knowing the true CP
matrix. For the SB this information is difﬁcult to obtain. An interesting project would therefore
be to evaluate the CP method in an organ where correlated motion of adjacent surface points
excist. Söhn and colleagues has developed a principal component based method which can be
used to generate reliable CPs for the rectum [81]. These could be compared with CPs estimated
with our method. Although the rectum have similarities with the SB, assuming that all voxels
with the same distance from the wall have approximately the same CP value is probably less
valid for the rectum because it is ﬁxed at one end. It would also be interesting to compare
CP-weighted DVHs/EUDs with accumulated DVHs/EUDs.
The methods developed in Paper IV in the current project require the SB contours from
a number of CT scans as input. Currently, these are manually outlined by an expert, which
is quite resource-intensive. Methods for automatic or semi-automatic segmentation of the SB
would therefore be of great assistance in clinical use of this method. In paralell with this PhD
project, a method for semi-automatic segmentation of the large bowel has been developed in
a connected PhD project [52]. It would be interesting to develop this method further to also
include semi-automatic segmentation of the small bowel.
In order to fully exploit the potential of pelvic IMRT it is crucial to establish reliable es-
timates of evaluators of plan quality. With the tools developed in the current work, we are
able to better pinpoint conﬂicting areas of SB and TV, but ﬁnding a compromise of dose to
these regions remain challenging because of an unclear dose-volume relationship. Another
main focus area of future work will therefore be to correlate patient-speciﬁc SB PRV DVHs
and CP-weighted DVHs to incidence of GI adverse effects. With the low GI adverse effects
rates seen with IMRT such a study would have to include a large number of patients [63].
Even in a large study, the correlation could be jeopardized by imprecicion of grading, unclear
cause-effect relation of speciﬁc sympthoms (especially for diarrhea), variability in small bowel
radiosensitivity between patients, and limitations of surrogate DVHs to representing the real
accumulated SB DVH. Despite these challenges, we believe that the SB planning concepts
developed in Paper IV of the current project can safely be used clinically and a clinical im-
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plementation of these methods both for locally advanced prostate cancer patients, but also for
bladder cancer patients and patients with gyneacological cancer, would therefore be a main
focus of future work.
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